NYSE$USNA
USANA Health Sciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
USANA's financial performance was affected by strength in mainland China operations, offsetting softness in other markets facing inflationary pressures.
USANA Health Sciences reported a decrease in net sales and diluted EPS for Q1 2024 compared to Q1 2023. Net sales were $228 million, and diluted EPS was $0.86. The company is reiterating its fiscal year 2024 net sales and diluted EPS outlook.
- First quarter net sales were $228 million, an 8% decrease compared to Q1 2023.
- First quarter diluted EPS was $0.86, a 9% decrease compared to Q1 2023.
- Active Customers increased 1% compared to Q1 2023, totaling 494,000.
- The company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.
Headline financials
Revenue & EPS history
USANA · Revenue · Quarterly
$228M
Forward guidance
The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows: Consolidated Net Sales $850 - $920 million and Diluted EPS $2.40 - $3.00.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+2.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.6%
Avg return
30 days after
58%
37 / 64 earnings
Positive
+39.2%
Q2 2015
Best reaction
-24.1%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | -9.7% | -7.0% | |
| Q3 2025 | -1.6% | -2.8% | -6.0% | |
| Q2 2025 | +4.1% | +0.8% | +1.5% | |
| Q1 2025 | +4.9% | +13.6% | +21.4% | |
| Q4 2024 | +3.9% | -6.2% | -13.1% | |
| Q3 2024 | +4.4% | +5.0% | +12.3% | |
| Q2 2024 | -3.7% | -7.7% | -14.6% | |
| Q1 2024 | +6.0% | +6.0% | +8.7% | |
| Q4 2023 | +7.1% | +9.6% | +4.6% | |
| Q3 2023 | -16.7% | -17.7% | -13.8% | |
| Q2 2023 | +6.5% | +2.1% | -0.3% | |
| Q1 2023 | +4.9% | +2.5% | -4.4% | |
| Q4 2022 | +4.7% | +4.0% | +2.4% | |
| Q3 2022 | -0.2% | -3.0% | -6.5% | |
| Q2 2022 | +1.1% | +1.4% | -0.5% | |
| Q1 2022 | -3.6% | -2.6% | -10.4% | |
| Q4 2021 | -8.4% | -5.2% | -10.1% | |
| Q3 2021 | -8.0% | -3.4% | +1.3% | |
| Q2 2021 | -2.3% | -6.8% | -6.9% | |
| Q1 2021 | -7.7% | -6.4% | +9.4% | |
| Q4 2020 | +15.7% | +6.3% | +16.4% | |
| Q3 2020 | +5.1% | +10.7% | -3.5% | |
| Q2 2020 | -6.4% | -12.4% | -8.8% | |
| Q1 2020 | +17.5% | +25.2% | +23.8% | |
| Q4 2019 | +25.3% | +28.1% | +15.7% | |
| Q3 2019 | +11.5% | +4.8% | +1.8% | |
| Q2 2019 | +0.3% | +6.1% | +5.7% | |
| Q1 2019 | +9.4% | +2.2% | -12.9% | |
| Q4 2018 | -11.4% | -6.5% | -18.1% | |
| Q3 2018 | +3.5% | +2.7% | +13.0% | |
| Q2 2018 | +23.9% | +18.9% | +19.0% | |
| Q1 2018 | +11.6% | +10.3% | +22.2% | |
| Q4 2017 | +5.6% | +7.0% | +14.4% | |
| Q3 2017 | +12.5% | +9.7% | +10.1% | |
| Q2 2017 | -10.0% | -11.2% | -7.5% | |
| Q1 2017 | +6.5% | +13.4% | +16.4% | |
| Q4 2016 | -11.6% | -8.9% | -8.9% | |
| Q3 2016 | -8.2% | -11.5% | -13.6% | |
| Q2 2016 | +11.6% | +8.2% | +8.4% | |
| Q1 2016 | +6.2% | — | — | |
| Q4 2015 | -24.1% | — | — | |
| Q3 2015 | -11.6% | — | — | |
| Q2 2015 | +39.2% | — | — | |
| Q1 2015 | +19.2% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +26.5% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | -15.2% | — | — | |
| Q4 2013 | +18.8% | — | — | |
| Q3 2013 | -9.6% | — | — | |
| Q2 2013 | -13.3% | — | — | |
| Q1 2013 | +8.1% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +1.7% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2010 | -4.2% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q3 2010 | -2.0% | — | — | |
| Q2 2010 | +4.3% | — | — | |
| Q1 2010 | +4.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro